Skip to main content

Table 1 Clinical characteristics of the study population

From: Effect of erythropoietin-stimulating agent on uremic inflammation

Age, years 65.5 ± 13.7
Male sex (%) 611 (67.9)
BMI, kg/m2 23.0 ± 4.0
SBP, mmHg 153 ± 26
DBP, mmHg 78 ± 15
CTR, % 54 ± 7
Primary disease  
Chronic glomeruronephritis 226 (25.1)
Diabetic nephropathy 432 (48.0)
Glomerulosclerosis 104 (11.6)
Polycystic kidney disease 28 (3.1)
Post-renal disease 5 (0.6)
Others 105 (11.6)
Duration of nephrologist care, months 33 ± 43
WBC, /mm3 6160 ± 1270
Hemoglobin, g/dL 8.5 ± 1.5
Plt x 104, mm3 19.4 ± 7.1
Albumin, g/dL 3.3 ± 0.6
LDL-C, mg/dL 98 ± 41
HDL-C, mg/dL 47 ± 17
Creatinin, mg/dL 9.5 ± 3.5
BUN, mg/dL 89 ± 27
Uric acid, mg/dL 8.6 ± 2.2
eGFR, mL/min/1.73 m2 5.4 ± 2.9
Calcium, mg/dL 7.8 ± 1.0
Phosphate, mg/dL 6.0 ± 1.6
Intact-PTH, pg/mL 304 ± 214
CRP, mg/dL 0.48 ± 0.68
HCO3-, mmol/L 18.9 ± 5.0
ESA (%) 614 (68.2)
ESA dose, u/month 17813 ± 6580
ARB (%) 489 (54.3)
ACE-I (%) 165 (16.3)
ARB or ACE-I (%) 541 (60.1)
ARB and ACE-I (%) 113 (12.6)
CCB (%) 565 (62.8)
other anti-HT drugs (%) 315 (35.0)
Vitamin D (%) 174 (19.3)
Calcium agents (%) 271 (30.1)
Iron agents (%) 85 (9.4)
AST-120 (%) 160 (17.8)
  1. BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, CTR; Cardiothoracic ratio, WBC; white blood cell, Plt; platelets, LDL-C; low density lipoprotein cholesterol, HDL-C; high density lipoprotein cholesterol, BUN; blood urea nitrogen, eGFR; estimated glomerular filtration rate, PTH; parathyroid hormone, CRP; C-reactive protein, ESA; erythropoietin-stimulating agents, ARB; angiotensin-II receptor blockers, ACE-I; angiotensin-converting enzyme inhibitors, CCB; calcium channel blockers, anti-HT; antihypertensive.